Acuta Capital Partners, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Acuta Capital Partners, LLC reported 23 stock positions worth $143.5 million. Its top holding was Praxis Precision Medicines I (PRAX) at 19.3% of the portfolio, followed by Whitehawk Therapeutics (WHWK, 15.0%) and Tango Therapeutics (TNGX, 8.5%). Compared with Q1 2026, it opened 5 new positions, sold out of 8, added to 9 and reduced 6. The biggest buy was Whitehawk Therapeutics (WHWK, shares +37%) and the biggest sale an exit from Terns Pharmaceuticals (TERN).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $143.5M (Q2 2026)
- SEC Filing
- 0001104659-26-096822 ↗ filed Aug 14, 2026
Holdings Value
Holdings 23 stocks · $143.5M
| PRAX Praxis Precision Medicines I | 19.32% | 82,796 | $27.7M | Reduce -2.5% |
| WHWK Whitehawk Therapeutics Inc. | 14.96% | 4,685,912 | $21.5M | Add +37.4% |
| TNGX Tango Therapeutics Inc. | 8.52% | 390,949 | $12.2M | Reduce -11.5% |
| STRO Sutro Biopharma Inc. | 6.25% | 270,251 | $9.0M | Add +0.3% |
| AVBP Arrivent Biopharma Inc. | 5.29% | 218,694 | $7.6M | New |
| FDMT 4D Molecular Therapeutics Inc. | 4.71% | 507,801 | $6.8M | New |
| DRUG Bright Minds Biosciences Inc. | 4.54% | 92,745 | $6.5M | Reduce -17.2% |
| OCUL Ocular Therapeutix Inc. | 3.64% | 532,481 | $5.2M | Reduce -10.1% |
| ERAS Erasca Inc. | 3.39% | 265,199 | $4.9M | Reduce -25.2% |
| SRZN Surrozen Inc. | 3.14% | 173,395 | $4.5M | Add +0.3% |
| ARGX Argenx SE - ADR | 3.04% | 4,705 | $4.4M | Add +0.3% |
| MLTX Moonlake Immunotherapeutics | 2.93% | 215,652 | $4.2M | Add +12.5% |
| DSGN Design Therapeutics Inc. | 2.85% | 282,564 | $4.1M | Add +93.7% |
| NERV Minerva Neurosciences Inc. | 2.74% | 709,500 | $3.9M | No change |
| TSHA Taysha Gene Therapies Inc. | 2.67% | 561,808 | $3.8M | Add +27.8% |
| AVLN Avalyn Pharma Inc. | 2.64% | 115,000 | $3.8M | New |
| AVTX Avalo Therapeutics Inc. | 2.40% | 186,308 | $3.4M | Add +206.4% |
| AMLX Amylyx Pharmaceuticals Inc. | 2.10% | 168,115 | $3.0M | Add +11.3% |
| ARTV Artiva Biotherapeutics Inc. | 1.76% | 260,416 | $2.5M | New |
| CMPX Compass Therapeutics Inc. | 0.91% | 595,213 | $1.3M | Reduce -29.9% |
| UTHR United Therapeutics Corp. | 0.84% | 2,224 | $1.2M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 0.72% | 63,095 | $1.0M | New |
| LBRX LB Pharmaceuticals Inc. | 0.65% | 28,919 | $939K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −18.59 |
| CMPX Compass Therapeutics Inc. | Reduce -29.9% | 0.91% | −2.29 |
| OCS Oculis Holding AG | Sold out | 0.00% | −1.86 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −1.80 |
| 4D MOLECULAR THERAPEUTICS IN | Sold out | 0.00% | −1.60 |
| DRUG Bright Minds Biosciences Inc. | Reduce -17.2% | 4.54% | −1.28 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −1.14 |
| TRDA Entrada Therapeutics Inc. | Sold out | 0.00% | −0.80 |
| ERAS Erasca Inc. | Reduce -25.2% | 3.39% | −0.69 |
| MAZE Maze Therapeutics Inc. | Sold out | 0.00% | −0.41 |
| UNCY Unicycive Therapeutics Inc. | Sold out | 0.00% | −0.27 |
| PRAX Praxis Precision Medicines I | Reduce -2.5% | 19.32% | −0.14 |
| OCUL Ocular Therapeutix Inc. | Reduce -10.1% | 3.64% | +0.08 |
| TNGX Tango Therapeutics Inc. | Reduce -11.5% | 8.52% | +1.94 |
Portfolio Buys Q1 2026 → Q2 2026
| WHWK Whitehawk Therapeutics Inc. | Add +37.4% | 14.96% | +6.59 |
| AVBP Arrivent Biopharma Inc. | New | 5.29% | +5.29 |
| FDMT 4D Molecular Therapeutics Inc. | New | 4.71% | +4.71 |
| AVLN Avalyn Pharma Inc. | New | 2.64% | +2.64 |
| ARTV Artiva Biotherapeutics Inc. | New | 1.76% | +1.76 |
| AVTX Avalo Therapeutics Inc. | Add +206.4% | 2.40% | +1.75 |
| DSGN Design Therapeutics Inc. | Add +93.7% | 2.85% | +1.75 |
| STRO Sutro Biopharma Inc. | Add +0.3% | 6.25% | +1.48 |
| TSHA Taysha Gene Therapies Inc. | Add +27.8% | 2.67% | +1.27 |
| CTNM Contineum Therapeutics Inc. Class A | New | 0.72% | +0.72 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +11.3% | 2.10% | +0.61 |
| ARGX Argenx SE - ADR | Add +0.3% | 3.04% | +0.61 |
| MLTX Moonlake Immunotherapeutics | Add +12.5% | 2.93% | +0.38 |
| SRZN Surrozen Inc. | Add +0.3% | 3.14% | −0.45 |
Options Activity Q1 2026 → Q2 2026
| IDYA Ideaya Biosciences Inc. | call | Sold out | 350 | $1.2Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |